CIPROFLOXACIN INJECTION DIN 02377535
Status: Cancelled Post Market
Holder: OMEGA LABORATORIES LIMITED
Molecule: CIPROFLOXACIN (CIPROFLOXACIN LACTATE)
Health Canada record
| Active ingredient(s) | CIPROFLOXACIN (CIPROFLOXACIN LACTATE) 2 MG |
|---|---|
| Dosage form | Solution |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | J01MA02 CIPROFLOXACIN |
| Original market date | 17-Apr-2012 |
| Current status date | 13-Mar-2019 |
| Source | Health Canada DPD |
Establishment licence of the holder
Omega Laboratories Ltd. (now Juno Pharma Canada Inc.) — licence 100277, not currently licensed, last inspection rating C (2025-05-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing CIPROFLOXACIN (CIPROFLOXACIN LACTATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02155982 | CIPRO I.V. - LIQ 10MG/ML | BAYER INC | Liquid | CIPROFLOXACIN (CIPROFLOXACIN LACTATE) 10 MG | Cancelled Post Market |
| 01947710 | CIPRO IV 10MG/ML | MILES CANADA INC. - PHARMACEUTICAL DIVISION | Liquid | CIPROFLOXACIN (CIPROFLOXACIN LACTATE) 10 MG | Cancelled Post Market |
| 02274140 | CIPROFLOXACIN INJECTION | FRESENIUS KABI CANADA LTD | Solution | CIPROFLOXACIN (CIPROFLOXACIN LACTATE) 10 MG | Cancelled Pre Market |
| 02301296 | CIPROFLOXACIN INJECTION | BAXTER CORPORATION | Solution | CIPROFLOXACIN (CIPROFLOXACIN LACTATE) 2 MG | Cancelled Post Market |
| 02464942 | CIPROFLOXACIN INJECTION | STERIMAX INC | Solution | CIPROFLOXACIN (CIPROFLOXACIN LACTATE) 0.2 % | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 12940 | 2012-01-19 | Abbreviated New Drug Submission (ANDS) | New manufacturer and oriduct name |